4D Molecular Therapeutics (FDMT) Cash & Equivalents (QoQ) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Cash & Equivalents (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | 4D Molecular Therapeutics | 704.47 Mn | 313.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.33% |
| Dec 31, 2025 | 24.07% |
| Sep 30, 2025 | -37.07% |
| Jun 30, 2025 | -42.21% |
| Mar 31, 2025 | -10.59% |
| Dec 31, 2024 | -20.37% |
| Sep 30, 2024 | -0.81% |
| Jun 30, 2024 | -31.40% |
| Mar 31, 2024 | 10.63% |
| Dec 31, 2023 | -9.64% |
| Sep 30, 2023 | 16.66% |
| Jun 30, 2023 | 200.77% |
| Mar 31, 2023 | 50.08% |
| Dec 31, 2022 | -51.66% |
| Sep 30, 2022 | -4.57% |
| Jun 30, 2022 | 49.38% |
| Mar 31, 2022 | -50.35% |
| Dec 31, 2021 | 68.15% |
| Sep 30, 2021 | -62.67% |
| Jun 30, 2021 | -6.20% |